What is Zacks Research's Estimate for PBYI FY2024 Earnings?

Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Investment analysts at Zacks Research lowered their FY2024 earnings per share estimates for Puma Biotechnology in a note issued to investors on Thursday, January 9th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings per share of $0.31 for the year, down from their prior forecast of $0.32. The consensus estimate for Puma Biotechnology's current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology's Q1 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.13 EPS, Q1 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.07 EPS and FY2026 earnings at $0.25 EPS.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.31 by $0.10. The firm had revenue of $80.50 million for the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. During the same period last year, the company posted $0.12 EPS.

Other equities research analysts have also issued research reports about the company. StockNews.com lowered Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a research report on Friday, December 6th. HC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of Puma Biotechnology in a report on Monday, December 23rd.

Puma Biotechnology Stock Down 3.3 %

Shares of PBYI traded down $0.11 during midday trading on Monday, hitting $3.20. The stock had a trading volume of 419,125 shares, compared to its average volume of 1,109,723. The firm has a market cap of $157.08 million, a price-to-earnings ratio of 6.67 and a beta of 1.10. The company has a 50 day simple moving average of $3.06 and a two-hundred day simple moving average of $2.99. Puma Biotechnology has a twelve month low of $2.22 and a twelve month high of $7.73. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in Puma Biotechnology during the third quarter worth approximately $34,000. Franklin Resources Inc. bought a new stake in Puma Biotechnology in the 3rd quarter valued at $41,000. Dynamic Technology Lab Private Ltd acquired a new position in Puma Biotechnology in the 3rd quarter valued at $44,000. Patriot Financial Group Insurance Agency LLC increased its position in Puma Biotechnology by 72.7% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company's stock worth $48,000 after buying an additional 8,000 shares during the period. Finally, Royce & Associates LP lifted its holdings in shares of Puma Biotechnology by 71.8% during the third quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company's stock worth $51,000 after buying an additional 8,427 shares in the last quarter. 61.29% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Puma Biotechnology

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 33,841 shares of the company's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total transaction of $106,599.15. Following the sale, the chief executive officer now directly owns 7,029,674 shares of the company's stock, valued at approximately $22,143,473.10. This represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of Puma Biotechnology stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total transaction of $29,726.55. Following the completion of the transaction, the insider now directly owns 108,951 shares of the company's stock, valued at approximately $343,195.65. This trade represents a 7.97 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 23.70% of the company's stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.